These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27746105)

  • 1. Daratumumab improves survival in multiple myeloma.
    Baker H
    Lancet Oncol; 2016 Nov; 17(11):e480. PubMed ID: 27746105
    [No Abstract]   [Full Text] [Related]  

  • 2. Daratumumab combination prolongs myeloma survival.
    Das M
    Lancet Oncol; 2016 Oct; 17(10):e422. PubMed ID: 27601427
    [No Abstract]   [Full Text] [Related]  

  • 3. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onartuzumab ineffective in non-small-cell lung cancer.
    Brower V
    Lancet Oncol; 2017 Feb; 18(2):e66. PubMed ID: 28017663
    [No Abstract]   [Full Text] [Related]  

  • 6. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of melanoma combination immunotherapy.
    Baker H
    Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
    [No Abstract]   [Full Text] [Related]  

  • 8. Daratumumab for the Treatment of Multiple Myeloma.
    Plesner T; Krejcik J
    Front Immunol; 2018; 9():1228. PubMed ID: 29915586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
    Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
    Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
    Paul B; Atrash S; Bhutani M; Voorhees P; Hamadeh I; Usmani SZ
    Expert Rev Hematol; 2020 Aug; 13(8):795-802. PubMed ID: 32659139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.
    Hofmeister CC; Lonial S
    J Clin Oncol; 2016 Dec; 34(36):4421-4430. PubMed ID: 27998219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
    Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
    N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area].
    Scheid C; Munder M; Salwender H; Engelhardt M
    Dtsch Med Wochenschr; 2018 Aug; 143(16):1201-1206. PubMed ID: 29874684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential biomarker for acute myeloid leukaemia therapy.
    Gourd E
    Lancet Oncol; 2017 Aug; 18(8):e438. PubMed ID: 28669738
    [No Abstract]   [Full Text] [Related]  

  • 15. NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.
    Elsada A; Adler AI
    Lancet Oncol; 2019 May; 20(5):619-620. PubMed ID: 30981602
    [No Abstract]   [Full Text] [Related]  

  • 16. A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma.
    Spencer A; Walker P; Asvadi P; Campbell DH; Reed K; Herbert BR; Breen EJ; Copeman MC; Dunn RD
    Blood Cancer J; 2019 Jul; 9(8):58. PubMed ID: 31366914
    [No Abstract]   [Full Text] [Related]  

  • 17. Infectious and immunological sequelae of daratumumab in multiple myeloma.
    Johnsrud AJ; Johnsrud JJ; Susanibar SA; Kamimoto JJ; Kothari A; Burgess M; Van Rhee F; Rico JC
    Br J Haematol; 2019 Apr; 185(1):187-189. PubMed ID: 29974956
    [No Abstract]   [Full Text] [Related]  

  • 18. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
    Laubach JP; Paba Prada CE; Richardson PG; Longo DL
    Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib therapy improves quality of life in multiple myeloma.
    Das M
    Lancet Oncol; 2016 Oct; 17(10):e427. PubMed ID: 27641476
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab biosimilar shows potential for breast cancer.
    Baker H
    Lancet Oncol; 2017 Jan; 18(1):e4. PubMed ID: 27956154
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.